US 11,774,784 B2
Optical system for treating chronobiological disorders and/or myopia
Coralie Barrau, Charenton-le-Pont (FR); Denis Cohen Tannoudji, Charenton-le-Pont (FR); and Thierry Villette, Charenton-le-Pont (FR)
Assigned to Essilor International, Charenton-le-Pont (FR)
Filed by ESSILOR INTERNATIONAL, Charenton-le-Pont (FR)
Filed on Feb. 3, 2021, as Appl. No. 17/248,704.
Application 17/248,704 is a continuation of application No. 16/092,662, granted, now 10,942,373, previously published as PCT/EP2017/058554, filed on Apr. 10, 2017.
Claims priority of application No. 16305422 (EP), filed on Apr. 11, 2016.
Prior Publication US 2021/0157172 A1, May 27, 2021
Int. Cl. G02C 7/10 (2006.01); A61N 5/06 (2006.01); G02B 27/01 (2006.01); A61F 9/02 (2006.01); G02B 5/20 (2006.01); G02B 5/28 (2006.01)
CPC G02C 7/104 (2013.01) [A61F 9/022 (2013.01); A61N 5/0618 (2013.01); G02B 5/20 (2013.01); G02B 5/28 (2013.01); G02B 27/0172 (2013.01); G02C 7/107 (2013.01); A61N 2005/063 (2013.01); A61N 2005/0626 (2013.01); A61N 2005/0648 (2013.01); A61N 2005/0651 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/0663 (2013.01); A61N 2005/0667 (2013.01); G02B 2027/0174 (2013.01); G02B 2027/0178 (2013.01); G02C 2202/24 (2013.01)] 13 Claims
OG exemplary drawing
 
1. An optical system having a spectral transmission profile having an average transmittance Ta between 380 nm and 780 nm and an average red light transmittance Tr between a first limit L1 and a second limit L2, with Tr<2*Ta/3 and L1=600 nm and L2=780 nm, and the optical system being configured to allow selectively retinal exposure of an eye to at least one selected range of wavelengths of light in the visible spectrum of 460 nm to 530 nm, wherein the optical system further comprises at least a luminescent agent which emits light within the at least one selected range of wavelengths of light; wherein the luminescence agent is a fluorescent material which emits light by fluorescence in the at least one selected range of wavelengths; and wherein the fluorescent material comprises fluorescent nanoparticles, wherein the fluorescent nanoparticles are quantum dots.